Regulatory Expanded US Imaavy approval first ever for wAIHA PharmaphorumThe FDA has approved Johnson Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).HematologyRead full story pharminent August 25, 2026 (Last updated: August 26, 2026) Pharmaphorum The FDA has approved Johnson Johnson’s Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA). Hematology Read full story Post navigation Previous: Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failNext: China’s Haisco forms immunology biotech with up to $1.5B from American VCs Related Stories Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026 Regulatory Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test pharminent August 25, 2026 Regulatory FDA greenlights Roche’s biomarker blood test for Alzheimer’s pharminent August 25, 2026
